Cargando…
Rechallenge of immune checkpoint inhibitors in a case with adverse events inducing myasthenia gravis
The mechanism(s) of immune checkpoint inhibitor (ICI)-induced myasthenia gravis (MG), an immune-related adverse event (irAE) that is fatal and limits subsequent ICI use, remain unexplored. Here, through comparative genomic analysis, we identified a pathogenic p.S467C germline variant in SLC22A5 in a...
Autores principales: | Gao, Wen, Wu, Lingxiang, Jin, Shidai, Li, Jun, Liu, Xinyin, Xu, Jiali, Zhang, Wei, Gong, Qixing, Sun, Chunxiao, Wang, Wei, Wang, Zidun, Shao, Yang W, Yin, Jiani C, Shen, Lu, Chen, Liang, Wang, Qianghu, Guo, Renhua |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9716945/ https://www.ncbi.nlm.nih.gov/pubmed/36450378 http://dx.doi.org/10.1136/jitc-2022-005970 |
Ejemplares similares
-
Immune Checkpoint Inhibitor-Induced Myasthenia Gravis
por: Huang, Yi-Te, et al.
Publicado: (2020) -
Rituximab for Immune Checkpoint Inhibitor Myasthenia Gravis
por: Verma, Neha, et al.
Publicado: (2021) -
Analysis on the risk of myasthenia gravis related to immune checkpoint inhibitors based on the US FDA Adverse Event Reporting System
por: Kong, Qingli, et al.
Publicado: (2023) -
Adverse Events Releated to Antibiotic Use in Patients with Myasthenia Gravis
por: Zeitler, Kristen, et al.
Publicado: (2017) -
Immune checkpoint inhibitors in the onset of myasthenia gravis with hyperCKemia
por: Takamatsu, Koutaro, et al.
Publicado: (2018)